Biliary tract cancers (BTCs), a heterogeneous group of cancers arising from the biliary tract, account for ∼15% of primary liver cancers. Patients are often diagnosed with advanced disease, resulting in poor prognoses and documented 5-year survival rates of <2%. The aim of this study was to describe real-world treatment patterns and outcomes among patients with advanced BTC in France, Germany, Italy, Spain, and the UK.

Neoadjuvant chemotherapy (NAC) with the addition of pembrolizumab has become the standard of care for early-stage II-III triple-negative breast cancer (TNBC). The real-world safety of this regimen is critical to assess in this subset of patients treated with curative intent, since many of the immune-related events observed can be long-lasting or irreversible.

Investing in cancer prevention can be cost-effective. However, this requires significant changes both inside and outside the health care system. The core of the preventive strategy is the assignment of an individual risk level of developing cancer. Artificial intelligence (AI), which has emerged as a tool to reduce errors and confusion in data collection and analysis, has helped accelerate recent advances in identifying circulating markers to generate predictive methods. With predictive models applied to increasingly less invasive and repeatable analytic tests, the risk is no longer assigned but profiled directly on the individual over time.